A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 316 participants.

Also called NCT02012075

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 316 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02012075
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02012075. Randomized; double masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2015-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
Condition
Heart Failure
Intervention (Drug)
Extended-Release Carvedilol Sulfate
Intervention (Drug)
Sustained-release Metoprolol Succinate
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02012075
Content hash
1cdb431ba0e67faeeab55c46eac70587535eae00d6e185cf59feaa580651f517